Melbourne, Australia, 11 March 2021: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
Today kidney health awareness becomes a focus globally during World Kidney Day. This awareness day precedes Australia’s Kidney Health Week which takes place 15-21 March 2021.
OccuRx, is proud to increase global awareness around kidney health.
“Today and next week are extremely important events in increasing awareness around kidney health. We’re proud to be developing innovative treatments to preserve kidney function, manage complications and improve quality of life by addressing both diabetic and non-diabetic kidney disease.” said Professor Darren Kelly, Executive Chair of OccuRx.
OccuRx is dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure. The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
There are currently no treatments available for kidney fibrosis, which presents in the majority of chronic kidney disease (CKD) patients. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs. OccuRx is using genetic analysis to identify the most suitable patients for treatment.